Metabolic Disorders and Male Hypogonadotropic Hypogonadism
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Several studies highlight that testosterone deficiency is associated with, and predicts, an increased risk of developing metabolic disorders, and, on the other hand, is highly prevalent in obesity, metabolic syndrome and type-2 diabetes mellitus. Models of gonadotropin releasing hormone deficiency, and androgen deprivation therapy in patients with prostate cancer, suggest that hypogonadotropic hypogonadism might contribute to the onset or worsening of metabolic conditions, by increasing visceral adiposity and insulin resistance. Nevertheless, in functional hypogonadism, as well as in late onset hypogonadism, the relationship between hypogonadotropic hypogonadism and metabolic disorders is bidirectional, and a vicious circle between the two components has been documented. The mechanisms underlying the crosstalk between testosterone deficiency and metabolic disorders include increased visceral adipose tissue and insulin resistance, leading to development of metabolic disorders, which in turn contribute to a further reduction of testosterone levels. The decrease in testosterone levels might be determined by insulin resistance-mediated and, possibly, pro-inflammatory cytokine-mediated decrease of sex hormone binding globulin, resulting in a temporary increased free testosterone available for aromatization to estradiol in visceral adipose tissue, followed by a subsequent decrease in free testosterone levels, due to the excess of visceral adipose tissue and aromatization; by a direct inhibitory effect of increased leptin levels on Leydig cells; and by a reduced gonadotropin secretion induced by estradiol, inflammatory mediators, leptin resistance, and insulin resistance, with the ultimate determination of a substantial hypogonadotropic hypogonadism. The majority of studies focusing on the effects of testosterone replacement therapy on metabolic profile reported a beneficial effect of testosterone on body weight, waist circumference, body mass index, body composition, cholesterol levels, and glycemic control. Consistently, several interventional studies demonstrated that correction of metabolic disorders, in particular with compounds displaying a greater impact on body weight and insulin resistance, improved testosterone levels. The aim of the current review is to provide a comprehensive overview on the relationship between hypogonadotropic hypogonadism and metabolism, by clarifying the independent role of testosterone deficiency in the pathogenesis of metabolic disorders, and by describing the relative role of testosterone deficiency and metabolic impairment, in the context of the bidirectional relationship between hypogonadism and metabolic diseases documented in functional hypogonadotropic hypogonadism. These aspects will be assessed by describing metabolic profile in men with hypogonadotropic hypogonadism, and androgenic status in men with metabolic disorders; afterwards, the reciprocal effects of testosterone replacement therapy and corrective interventions on metabolic derangements will be reported.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of Brain Insulin Receptor in Control of Body Weight and Reproduction
Brüning, J. C., Gautam, D., Burks, D. J., Gillette, J., Schubert, M., Orban, P. C., Klein, R., Krone, W., Müller-Wieland, D., & Kahn, C. R. (2000) · Science · doi:10.1126/science.289.5487.2122 · Cited by 2,235 · cited 1×
“On the other side, experimental animal models demonstrated that insulin exerts a stimulatory action on hypothalamic GnRH neurons, which results in gonadotropin release, therefore suggesting that IR associated with metabolic disorders might reduce gonadotropin secretion and promote hypogonadism (31).”
BackgroundDing, E. L., Song, Y., Malik, V. S., & Liu, S. (2006) · JAMA · doi:10.1001/jama.295.11.1288 · Cited by 1,354
Laaksonen, D. E., Niskanen, L., Punnonen, K., Nyyssönen, K., Tuomainen, T.-P., Valkonen, V.-P., Salonen, R., & Salonen, J. T. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1036 · Cited by 920 · cited 1×
“A population-based prospective cohort study on 702 middle-aged men without MetS or T2-DM at baseline demonstrated that men with total testosterone (TT) or calculated free testosterone (FT) or sex hormone binding globulin (SHBG) levels in the lowest quartile had an increased risk of developing MetS, when compared with…”
BackgroundInvestigation, treatment and monitoring of late-onset hypogonadism in males
Wang, C., Nieschlag, E., Swerdloff, R., Behre, H. M., Hellstrom, W. J., Gooren, L. J., Kaufman, J. M., Legros, J.-J., Lunenfeld, B., Morales, A., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0601 · Cited by 867
Katznelson, L., Finkelstein, J. S., Schoenfeld, D. A., Rosenthal, D. I., Anderson, E. J., & Klibanski, A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.12.8954042 · Cited by 791 · cited 1×
“In particular, one case-control study on 36 hypogonadal men, comprising 29 men with Hypo-H (20 with known cause and 9 idiopathic), and 7 men with Hyper-H, aged 22–68 years (median age 53 years), highlighted that TRT with 100mg intramuscular testosterone enanthate once per week for 18 months significantly decreased tot…”
BackgroundKapoor, D., Goodwin, E., Channer, K. S., & Jones, T. H. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02166 · Cited by 791 · cited 1×
“A double-blind randomized crossover study on 24 hypogonadal men (2 Hypo-H, 8 Hyper-H, 14 mixed) with T2-DM demonstrated that TRT with 200mg intramuscular testosterone propionate every 2 weeks for 3 months significantly reduced HbA1c and glucose levels, WC and waist/hip ratio, and significantly improved HOMA-IR, in pat…”
BackgroundPrevalence of hypogonadism in males aged at least 45 years: the HIM study
MULLIGAN, T., FRICK, M. F., ZURAW, Q. C., STEMHAGEN, A., & MCWHIRTER, C. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.00992.x · Cited by 767 · cited 1×
“A large study on 2098 men demonstrated that the prevalence of HypoH, with decreased TT, FT, and SHBG, was significantly higher in T2-DM patients, rather than patients without T2-DM (69).”
BackgroundChanges in body composition during androgen deprivation therapy for prostate cancer
Smith, M. R., Finkelstein, J. S., McGovern, F. J., Zietman, A. L., Fallon, M. A., Schoenfeld, D. A., & Kantoff, P. W. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8299 · Cited by 697 · cited 1×
“Moreover, differently from classical MetS, ADT-induced Hypo-H is associated with increased, rather than decreased, high-density lipoprotein (HDL) levels, and a preferential increase in subcutaneous adipose tissue, rather than VAT (47).”
BackgroundIsidori, A. M., Giannetta, E., Greco, E. A., Gianfrilli, D., Bonifacio, V., Isidori, A., Lenzi, A., & Fabbri, A. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02339.x · Cited by 695
Frequent Occurrence of Hypogonadotropic Hypogonadism in Type 2 Diabetes
Dhindsa, S., Prabhakar, S., Sethi, M., Bandyopadhyay, A., Chaudhuri, A., & Dandona, P. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0804 · Cited by 631 · cited 7×
“Moreover, additional studies highlighted that the association of testosterone deficiency with metabolic disorders frequently occurs in a clinical context of Hypo-H, and that Hypo-H is frequently reported in metabolic disorders, such as obesity, IR, MetS, and T2-DM (15, 19, 20).”
BackgroundResultInfluentialKeating, N. L., O'Malley, A. J., Freedland, S. J., & Smith, M. R. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp404 · Cited by 622
Oh, J.-Y., Barrett-Connor, E., Wedick, N. M., & Wingard, D. L. (2002) · Diabetes Care · doi:10.2337/diacare.25.1.55 · Cited by 594 · cited 1×
“Likewise, an increased risk of developing T2-DM was demonstrated in healthy men in the lowest quartile compared to those in the highest three quartiles of TT levels (13).”
BackgroundSeidell, J. C., Björntorp, P., Sjöström, L., Kvist, H., & Sannerstedt, R. (1990) · Metabolism · doi:10.1016/0026-0495(90)90297-p · Cited by 567
Kupelian, V., Page, S. T., Araujo, A. B., Travison, T. G., Bremner, W. J., & McKinlay, J. B. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1326 · Cited by 561
Effect of Testosterone Treatment on Body Composition and Muscle Strength in Men Over 65 Years of Age
Snyder, P. J. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.8.2647 · Cited by 531 · cited 1×
“Conversely, another double-blind randomized placebo-controlled study on 108 healthy men over 65 years of age, with testosterone levels 1 SD or more below the mean for normal young men (<475 ng/dL), demonstrated that treatment with transdermal testosterone at 6 mg/day aimed at raising testosterone levels to mid-normal…”
BackgroundTestosterone Replacement Increases Fat-Free Mass and Muscle Size in Hypogonadal Men1
Bhasin, S., Storer, T. W., Berman, N., Yarasheski, K. E., Clevenger, B., Phillips, J., Lee, W. P., Bunnell, T. J., & Casaburi, R. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.2.3733 · Cited by 522
Insulin sensitivity during combined androgen blockade for prostate cancer
Smith, M. R., Lee, H., & Nathan, D. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2507 · Cited by 493 · cited 1×
“ADT-induced Hypo-H in men with prostate cancer has been associated with increased fat mass (45–47), decreased insulin sensitivity (45, 48), and increased risk of MetS and T2-DM (49).”
BackgroundClinical and Biochemical Assessment of Hypogonadism in Men With Type 2 Diabetes
Kapoor, D., Aldred, H., Clark, S., Channer, K. S., & Jones, T. H. (2007) · Diabetes Care · doi:10.2337/dc06-1426 · Cited by 493 · cited 3×
“Moreover, VAT accumulation characterizing visceral obesity, results in increased aromatization of testosterone to estradiol (28, 30, 32) and enhanced action of inflammatory mediators, including tumor necrosis factor-a (TNF-a), interleukin-6 (IL-6), and interleukin-1b (IL-1b), shown to suppress hypothalamic GnRH, and,…”
BackgroundKelly, D. M., & Jones, T. H. (2015) · Obesity Reviews · doi:10.1111/obr.12282 · Cited by 487
Relationship Between Testosterone Levels, Insulin Sensitivity, and Mitochondrial Function in Men
Pitteloud, N., Mootha, V. K., Dwyer, A. A., Hardin, M., Lee, H., Eriksson, K.-F., Tripathy, D., Yialamas, M., Groop, L., Elahi, D., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1636 · Cited by 472
Low testosterone levels are common and associated with insulin resistance in men with diabetes
Grossmann, M., Thomas, M. C., Panagiotopoulos, S., Sharpe, K., MacIsaac, R. J., Clarke, S., Zajac, J. D., & Jerums, G. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2177 · Cited by 468 · cited 6×
“A different cross-sectional study on 580 men reported a prevalence of testosterone deficiency of 43% and 57%, by considering TT and calculated FT, respectively, in T2-DM, and of 7% and 20% in type-1 diabetes mellitus (T1-DM) (66).”
BackgroundResultInfluentialEffects of Testosterone Replacement in Hypogonadal Men
Snyder, P. J. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.8.2670 · Cited by 464
Sex hormones, inflammation and the metabolic syndrome: a population-based study
Laaksonen, D., Niskanen, L., Punnonen, K., Nyyssonen, K., Tuomainen, T., Salonen, R., Rauramaa, R., & Salonen, J. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1490601 · Cited by 438
Low serum testosterone and sex-hormone-binding-globulin in massively obese men
GLASS, A. R., SWERDLOFF, R. S., BRAY, G. A., DAHMS, W. T., & ATKINSON, R. L. (1977) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-45-6-1211 · Cited by 430 · cited 1×
“A crucial role in the crosstalk between metabolic disorders and testosterone deficiency has been attributed to SHBG levels, which have been shown to be reduced in obese men (37) and men with T2-DM (38), as well as to be negatively associated with the risk of MetS and T2-DM (39).”
BackgroundCorona, G., Rastrelli, G., Monami, M., Saad, F., Luconi, M., Lucchese, M., Facchiano, E., Sforza, A., Forti, G., Mannucci, E., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-12-0955 · Cited by 414
Type 2 diabetes mellitus and testosterone: a meta-analysis study: Type 2 diabetes and testosterone
Corona, G., Monami, M., Rastrelli, G., Aversa, A., Sforza, A., Lenzi, A., Forti, G., Mannucci, E., & Maggi, M. (2011) · International Journal of Andrology · doi:10.1111/j.1365-2605.2010.01117.x · Cited by 370
Heufelder, A. E., Saad, F., Bunck, M. C., & Gooren, L. (2009) · Journal of Andrology · doi:10.2164/jandrol.108.007005 · Cited by 349 · cited 2×
“(79) B Rnd 32 hypogonadal men with MetS and newly diagnosed T2-DM”
BackgroundMethodZUMOFF, B., STRAIN, G. W., MILLER, L. K., ROSNER, W., SENIE, R., SERES, D. S., & ROSENFELD, R. S. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-71-4-929 · Cited by 349
Vermeulen, A. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.76.5.1140 · Cited by 346
Novel insights in SHBG regulation and clinical implications
Simó, R., Sáez-López, C., Barbosa-Desongles, A., Hernández, C., & Selva, D. M. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.05.001 · Cited by 335
Mårin, P., Odén, B., & Björntorp, P. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.1.7829619 · Cited by 332
Basaria, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61126-5 · Cited by 328
Association of Bioavailable, Free, and Total Testosterone With Insulin Resistance
Tsai, E. C., Matsumoto, A. M., Fujimoto, W. Y., & Boyko, E. J. (2004) · Diabetes Care · doi:10.2337/diacare.27.4.861 · Cited by 307 · cited 1×
“Lastly, consistently with different studies in non-diabetic normal or overweight men with or without MetS (70, 71), calculated FT levels were negatively correlated with insulin levels, HOMA-IR and VAT, also in a cross-sectional cohort study on men with T2-DM, further supporting the hypothesis that IR reduces circulati…”
ResultAllan, C. A., Strauss, B. J. G., Burger, H. G., Forbes, E. A., & McLachlan, R. I. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1291 · Cited by 298
Barrett-Connor, E. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-10-807 · Cited by 281 · cited 1×
“On the other hand, observational studies demonstrated that obesity, mainly characterized by visceral adiposity, IR (14, 15), MetS (14–16), as well as T2-DM (14, 17, 18) are often associated with testosterone deficiency and predicts an increased risk of developing incident hypogonadism.”
BackgroundTestosterone concentrations in women and men with NIDDM
Andersson, B., Märin, P., Lissner, L., Vermeulen, A., & Björntorp, P. (1994) · Diabetes Care · doi:10.2337/diacare.17.5.405 · Cited by 268 · cited 2×
“A crucial role for IR, and compensatory hyperinsulinemia, in the suppression of SHBG levels has been strongly supported by a clear inverse relationship between serum insulin and SHBG levels (38, 41, 42).”
BackgroundGrossmann, M., & Matsumoto, A. M. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3580 · Cited by 246
Cohen, P. G. (1999) · Medical Hypotheses · doi:10.1054/mehy.1997.0624 · Cited by 245 · cited 1×
“Moreover, VAT accumulation characterizing visceral obesity, results in increased aromatization of testosterone to estradiol (28, 30, 32) and enhanced action of inflammatory mediators, including tumor necrosis factor-a (TNF-a), interleukin-6 (IL-6), and interleukin-1b (IL-1b), shown to suppress hypothalamic GnRH, and,…”
BackgroundLaaksonen, D. E., Niskanen, L., Punnonen, K., Nyyssönen, K., Tuomainen, T.-P., Valkonen, V.-P., & Salonen, J. T. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0970 · Cited by 230 · cited 10×
“A population-based prospective cohort study on 702 middle-aged men without MetS or T2-DM at baseline demonstrated that men with total testosterone (TT) or calculated free testosterone (FT) or sex hormone binding globulin (SHBG) levels in the lowest quartile had an increased risk of developing MetS, when compared with…”
BackgroundInfluentialHaffner, S. M., Valdez, R. A., Mykkänen, L., Stern, M. P., & Katz, M. S. (1994) · Metabolism · doi:10.1016/0026-0495(94)90202-x · Cited by 226 · cited 2×
“Some studies demonstrated that MetS is associated with testosterone deficiency, in particular in presence of obesity (59, 62, 63).”
BackgroundYialamas, M. A., Dwyer, A. A., Hanley, E., Lee, H., Pitteloud, N., & Hayes, F. J. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0454 · Cited by 220 · cited 1×
“Interestingly, one prospective cohort study on 12 young men with idiopathic GnRH deficiency demonstrated that insulin sensitivity was significantly reduced, and fasting insulin and IR, as assessed by HOMA-IR, were significantly increased, after 2 weeks of acute TRT withdrawal (43), demonstrating that testosterone defi…”
BackgroundPathogenesis of the decreased androgen levels in obese men.
Giagulli, V. A., Kaufman, J. M., & Vermeulen, A. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.79.4.7962311 · Cited by 215 · cited 2×
“FT levels were significantly lower in the latter group, and testosterone deficiency, according to FT levels, was detected only in severely obese subjects (53).”
BackgroundResultCorona, G., Rastrelli, G., & Maggi, M. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.05.002 · Cited by 177 · cited 3×
“Moreover, an inverse relationship was found between TT, FT, and SHBG with BMI (19), also confirmed by subsequent studies (21, 22).”
BackgroundResultSvartberg, J., Agledahl, I., Figenschau, Y., Sildnes, T., Waterloo, K., & Jorde, R. (2008) · International Journal of Impotence Research · doi:10.1038/ijir.2008.19 · Cited by 160
Interrelation between plasma testosterone and plasma insulin in healthy adult men: the Telecom Study
Simon, D., Preziosi, P., Barrett-Connor, E., Roger, M., Saint-Paul, M., Nahoul, K., & Papoz, L. (1992) · Diabetologia · doi:10.1007/bf00402551 · Cited by 157 · cited 1×
“Moreover, a cross-sectional cohort study on 1,292 healthy non-diabetic men demonstrated a negative correlation between TT and insulin levels, maintained after adjustment for age and obesity (61).”
BackgroundSaboor Aftab, S. A., Kumar, S., & Barber, T. M. (2013) · Clinical Endocrinology · doi:10.1111/cen.12092 · Cited by 157
Obesity and late-onset hypogonadism
Corona, G., Vignozzi, L., Sforza, A., Mannucci, E., & Maggi, M. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.06.031 · Cited by 154
Simon, D., Charles, M.-A., Lahlou, N., Nahoul, K., Oppert, J.-M., Gouault-Heilmann, M., Lemort, N., Thibult, N., Joubert, E., Balkau, B., et al. (2001) · Diabetes Care · doi:10.2337/diacare.24.12.2149 · Cited by 136 · cited 2×
“Additionally, a double-blind, randomized, placebo-controlled trial on 18 healthy non-obese hypogonadal men demonstrated that treatment with dihydrotestosterone gel at 35 mg/day for 3 months, aimed at normalizing testosterone levels, significantly Frontiers in Endocrinology | www.frontiersin.org 6 July 2019 | Volume 10…”
BackgroundYeap, B. B., Grossmann, M., McLachlan, R. I., Handelsman, D. J., Wittert, G. A., Conway, A. J., Stuckey, B. G., Lording, D. W., Allan, C. A., Zajac, J. D., et al. (2016) · Medical Journal of Australia · doi:10.5694/mja16.00393 · Cited by 135
Saad, F., Gooren, L. J., Haider, A., & Yassin, A. (2008) · Journal of Andrology · doi:10.2164/jandrol.107.002774 · Cited by 132
Giagulli, V. A., Carbone, M. D., Ramunni, M. I., Licchelli, B., De Pergola, G., Sabbà, C., Guastamacchia, E., & Triggiani, V. (2015) · Andrology · doi:10.1111/andr.12099 · Cited by 109
How to recognize late-onset hypogonadism in men with sexual dysfunction
Corona, G., Rastrelli, G., Vignozzi, L., Mannucci, E., & Maggi, M. (2012) · Asian Journal of Andrology · doi:10.1038/aja.2011.138 · Cited by 108 · cited 11×
“In conclusion, consistent evidences from clinical and experimental studies support the concept that Hypo-H may be an independent risk factor for metabolic disorders; moreover, specifically in LOH, a vicious circle hypothesis has been repeatedly demonstrated, linking Hypo-H to obesity, IR, MetS, and T2-DM in a bidirect…”
BackgroundResultInfluentialEffects of liraglutide on obesity-associated functional hypogonadism in men
Jensterle, M., Podbregar, A., Goricar, K., Gregoric, N., & Janez, A. (2019) · Endocrine Connections · doi:10.1530/ec-18-0514 · Cited by 101
Contrasting testosterone concentrations in type 1 and type 2 diabetes.
Tomar, R., Dhindsa, S., Chaudhuri, A., Mohanty, P., Garg, R., & Dandona, P. (2006) · Diabetes Care · doi:10.2337/dc06-0197 · Cited by 100
Partial androgen deficiency in aging type 2 diabetic men and its relationship to glycemic control
Corrales, J. J., Burgo, R. M., Garcı́a-Berrocal, B., Almeida, M., Alberca, I., González-Buitrago, J. M., Orfao, A., & Miralles, J. M. (2004) · Metabolism · doi:10.1016/j.metabol.2003.12.016 · Cited by 97
Corona, G., Mannucci, E., Forti, G., & Maggi, M. (2009) · International Journal of Andrology · doi:10.1111/j.1365-2605.2009.00965.x · Cited by 96
Saad, F., Gooren, L., Haider, A., & Yassin, A. (2007) · Archives of Andrology · doi:10.1080/01485010701730880 · Cited by 87
Tripathy, D., Shah, P., Lakshmy, R., & Reddy, K. (1998) · Hormone and Metabolic Research · doi:10.1055/s-2007-978950 · Cited by 66
Huang, G., Pencina, K. M., Li, Z., Basaria, S., Bhasin, S., Travison, T. G., Storer, T. W., Harman, S. M., & Tsitouras, P. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02545 · Cited by 40 · cited 1×
“5 g with dose titration according to TT levels, did not improve insulin sensitivity, as demonstrated by unchanged steady-state plasma glucose concentration at equilibrium, a direct measure of the ability of exogenous insulin to mediate disposal of an infused glucose load under steady-state conditions, during which end…”
BackgroundGyawali, P., Martin, S. A., Heilbronn, L. K., Vincent, A. D., Jenkins, A. J., Januszewski, A. S., Taylor, A. W., Adams, R. J. T., O’Loughlin, P. D., & Wittert, G. A. (2018) · PLOS ONE · doi:10.1371/journal.pone.0200078 · Cited by 35 · cited 1×
“Moreover, visceral adiposity has been pointed out by a recent, large, prospective study, as being negatively correlated with SHBG levels (40).”
Background
Cited by
Erectile dysfunction and diabetes: A melting pot of circumstances and treatments
Defeudis, G., Mazzilli, R., Tenuta, M., Rossini, G., Zamponi, V., Olana, S., Faggiano, A., Pozzilli, P., Isidori, A. M., & Gianfrilli, D. (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3494 · Cited by 285
Huang, G., Pencina, K. M., Li, Z., Basaria, S., Bhasin, S., Travison, T. G., Storer, T. W., Harman, S. M., & Tsitouras, P. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02545 · Cited by 40
Functional hypogonadism among patients with obesity, diabetes, and metabolic syndrome
Louters, M., Pearlman, M., Solsrud, E., & Pearlman, A. (2022) · International Journal of Impotence Research · doi:10.1038/s41443-021-00496-7 · Cited by 32
Metabolism of testosterone during weight loss in men with obesity
Van de Velde, F., Deventer, K., Van Gansbeke, W., Van Eenoo, P., Van Renterghem, P., Fiers, T., Reyns, T., Kaufman, J. M., Van Nieuwenhove, Y., & Lapauw, B. (2021) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2021.105851 · Cited by 17
Kaltsas, A., Dimitriadis, F., Zachariou, A., Koukos, S., Chrisofos, M., & Sofikitis, N. (2026) · Cells · doi:10.3390/cells15020158 · Cited by 12
“Baseline gonadotropin levels and sex hormone-binding globulin (SHBG) provide additional context by distinguishing primary testicular failure from secondary hypogonadotropic dysfunction and by reflecting metabolic influences on androgen bioavailability [135].”
Metadata
- Authors
- Pivonello, R., Menafra, D., Riccio, E., Garifalos, F., Mazzella, M., de Angelis, C., & Colao, A.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2019-07-25
- Volume
- 10
- Pages
- 345-345
- ISSN
- 1664-2392 (ISSN-L)
- OpenAlex
- W2963380087
- Cited by
- 143
- References
- 60
- FWCI
- 9.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.